TD Waterhouse Canada Inc. grew its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 7.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 41,195 shares of the medical research company’s stock after purchasing an additional 2,855 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Quest Diagnostics were worth $7,145,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. JFS Wealth Advisors LLC increased its position in shares of Quest Diagnostics by 114.3% during the 4th quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock worth $26,000 after purchasing an additional 80 shares during the last quarter. Harbor Investment Advisory LLC increased its position in shares of Quest Diagnostics by 113.7% during the 4th quarter. Harbor Investment Advisory LLC now owns 156 shares of the medical research company’s stock worth $27,000 after purchasing an additional 83 shares during the last quarter. True Wealth Design LLC increased its position in shares of Quest Diagnostics by 369.7% during the 3rd quarter. True Wealth Design LLC now owns 155 shares of the medical research company’s stock worth $30,000 after purchasing an additional 122 shares during the last quarter. First Horizon Corp acquired a new position in shares of Quest Diagnostics during the 3rd quarter worth approximately $33,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Quest Diagnostics during the 3rd quarter worth approximately $33,000. Institutional investors and hedge funds own 88.06% of the company’s stock.
Trending Headlines about Quest Diagnostics
Here are the key news stories impacting Quest Diagnostics this week:
- Positive Sentiment: Q1 results beat and guidance raised — Quest reported adjusted EPS of $2.50 and revenue of $2.90B (≈+9.2% y/y) and raised FY‑2026 adjusted EPS to $10.63–$10.83 and revenue to ~$11.8–$11.9B, a clear catalyst for the stock moving higher. Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
- Positive Sentiment: Growth drivers called out — Coverage notes organic volume strength in routine diagnostic testing plus new partnerships and AI tools helped revenue and margin performance, supporting the higher outlook. Quest Diagnostics Gains Steam With Partnerships, Lifts Outlook
- Positive Sentiment: Wall Street reaction and analyst context — Several analysts and outlets emphasize the beat + guide as validation of execution; some firms maintain/raise targets and at least one recent buy rating is on record, supporting near‑term investor interest. Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX)…
- Neutral Sentiment: Earnings details and management commentary available — The earnings press release, slide deck and full earnings‑call transcript provide the specifics behind the beat and guidance for investors who want to vet margin drivers and segment performance. Quest Diagnostics Incorporated (DGX) Q1 2026 Earnings Call Transcript
- Negative Sentiment: Insider and institutional activity flagged — Data aggregators note sizable insider sales and notable institutional position reductions in recent quarters; while not tied to the quarter’s operational outlook, these flows could add selling pressure or limit upside for some investors. Quest Diagnostics rises after Q1 earnings beat and higher 2026 outlook
Analyst Ratings Changes
Get Our Latest Report on Quest Diagnostics
Quest Diagnostics Stock Performance
Shares of NYSE DGX opened at $205.12 on Wednesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.04 and a quick ratio of 0.96. The stock’s fifty day moving average price is $200.53 and its two-hundred day moving average price is $189.02. Quest Diagnostics Incorporated has a one year low of $164.65 and a one year high of $213.50. The firm has a market cap of $22.70 billion, a price-to-earnings ratio of 23.44, a P/E/G ratio of 2.54 and a beta of 0.66.
Quest Diagnostics (NYSE:DGX – Get Free Report) last released its earnings results on Tuesday, April 21st. The medical research company reported $2.50 earnings per share for the quarter, beating analysts’ consensus estimates of $2.37 by $0.13. The firm had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.83 billion. Quest Diagnostics had a return on equity of 15.57% and a net margin of 8.99%.The company’s revenue was up 9.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.94 EPS. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. On average, equities analysts forecast that Quest Diagnostics Incorporated will post 10.6 EPS for the current year.
Quest Diagnostics Increases Dividend
The business also recently announced a quarterly dividend, which was paid on Monday, April 20th. Stockholders of record on Monday, April 6th were given a dividend of $0.86 per share. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date was Monday, April 6th. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.80. Quest Diagnostics’s dividend payout ratio is currently 39.31%.
Quest Diagnostics announced that its board has authorized a share repurchase plan on Tuesday, February 10th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 4.7% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its stock is undervalued.
Insider Buying and Selling
In other news, EVP Catherine T. Doherty sold 5,558 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $206.21, for a total transaction of $1,146,115.18. Following the completion of the sale, the executive vice president directly owned 67,122 shares in the company, valued at approximately $13,841,227.62. This represents a 7.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Karthik Kuppusamy sold 2,628 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $204.86, for a total value of $538,372.08. Following the sale, the senior vice president owned 13,441 shares of the company’s stock, valued at approximately $2,753,523.26. The trade was a 16.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 24,083 shares of company stock valued at $4,945,262. 8.16% of the stock is owned by insiders.
Quest Diagnostics Profile
Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
See Also
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
